ETF Holdings Breakdown of ALLO

Stock NameAllogene Therapeutics Inc
TickerALLO(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS0197701065

News associated with ALLO

Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $9.29
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price […] - 2025-05-06 05:09:01
Legal & General Group Plc Decreases Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Legal & General Group Plc trimmed its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 11.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 112,235 shares of the company’s stock after selling 15,172 shares during the quarter. Legal & General Group Plc’s holdings in Allogene Therapeutics were worth $239,000 at the end […] - 2025-05-01 07:57:03
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 3.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 8,000,692 shares of the company’s stock after selling 327,007 shares during the period. Vanguard Group Inc.’s holdings in Allogene Therapeutics were worth $17,041,000 at the end […] - 2025-04-17 07:22:52
Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $9.29
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has received an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month price objective among […] - 2025-04-11 05:40:54
Allogene's ALLO-329 Granted Three FDA Fast Track Designations
(RTTNews) - Clinical-stage biotechnology company Allogene Therapeutics, Inc. (ALLO), Monday announced that ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic CAR T, has received three Fast Track Designations (FTD) from the U.S. Food and Drug Administration (FDA) for - 2025-04-07 15:57:11
Teacher Retirement System of Texas Boosts Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Teacher Retirement System of Texas raised its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 28.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 43,877 shares of the company’s stock after purchasing an additional 9,839 shares during the quarter. Teacher Retirement System of Texas’ holdings in Allogene Therapeutics were worth $93,000 […] - 2025-04-03 07:16:48
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Up 16.2% in February
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 39,100,000 shares, a growth of 16.2% from the February 13th total of 33,660,000 shares. Based on an average daily trading volume, of 5,120,000 […] - 2025-03-21 06:58:44
Allogene Therapeutics (NASDAQ:ALLO) Price Target Lowered to $8.00 at HC Wainwright
Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price objective decreased by HC Wainwright from $9.00 to $8.00 in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Other research analysts have also recently issued reports about the stock. Canaccord Genuity Group reissued a “buy” rating […] - 2025-03-20 07:44:59
Head to Head Analysis: Allogene Therapeutics (NASDAQ:ALLO) and DBV Technologies (NASDAQ:DBVT)
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) and DBV Technologies (NASDAQ:DBVT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations. Analyst Ratings This is a breakdown of […] - 2025-02-24 06:14:49

ALLO institutional holdings

The following institutional investment holdings of ALLO have been identified

Date ETF ISIN/Name Num Shares Book value
2025-02-27 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 87,347USD 170,327 -4.6%
2025-02-27 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 22,413USD 43,705 -4.6%
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 165,706USD 195,533
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 102,270USD 120,679
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 102,270USD 120,679 -1.7%
Total =480,006 USD 650,923
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.